Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

NCT06578546 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ph-Positive Acute Lymphoblastic Leukemia

Interventions

DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Orebatinib

Sponsor

The First Affiliated Hospital of Soochow University